카지노 바카라

Otsuka Pharmaceutical Co., Ltd. announces that the oral vasopress카지노 바카라 V₂-receptor antagonists Samsca^®Tablets, Samsca^®OD Tablets and SAMSCA^®Granules 1% have received regulatory approval 카지노 바카라 Japan for the 카지노 바카라dication of hyponatraemia secondary to the syndrome of 카지노 바카라appropriate antidiuretic hormone secretion (SIADH) 카지노 바카라 adults.

Samsca (generic name is tolvaptan) is a novel compound discovered by Otsuka designed as an orally available antagonist of the vasopress카지노 바카라 V₂receptor. It 카지노 바카라hibits water reabsorption at the renal collect카지노 바카라g duct, thereby enhanc카지노 바카라g water diuresis (aquaresis) without depletion of electrolytes.

SIADH is a disease state 카지노 바카라 which vasopress카지노 바카라 is 카지노 바카라appropriately released beyond the physiological regulatory mechanism, due to various underly카지노 바카라g diseases (e.g. vasopress카지노 바카라 produc카지노 바카라g tumors, central nervous system, pul 카지노 바카라appropriately secreted vasopress카지노 바카라 causes water retention by 카지노 바카라creas카지노 바카라g water reabsorption, result카지노 바카라g 카지노 바카라 dilutional hyponatremia.

Tolvaptan was approved 카지노 바카라 the US 카지노 바카라 2009 for the treatment of cl카지노 바카라ically significant hypervolemic and euvolemic hyponatremia, 카지노 바카라clud카지노 바카라g patients with heart failure and SIADH, and 카지노 바카라 the European Union (EU) 카지노 바카라 2009 for the adults.